chr17-68524078-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_002734.5(PRKAR1A):c.502+1G>A variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_002734.5 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 29161691, 21047926, 18445140) -
Carney complex, type 1 Pathogenic:1
For these reasons, this variant has been classified as Pathogenic. One experimental study using patient-derived lymphoblastoid cell lines has shown that this sequence change causes exon 5 skipping, creating a premature stop codon (PMID: 18445140). Loss-of-function variants in PRKAR1A are known to be pathogenic. This particular variant has been reported to segregate with Carney complex in one family (PMID: 18445140). This sequence change affects a donor splice site in intron 5 of the PRKAR1A gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.502+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 4 of the PRKAR1A gene. This alteration has been observed in at least one individual with a personal and/or family history that is consistent with Carney complex (Ambry internal data). Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNAdecay; however, direct evidence is unavailable. The exact functional effect of the altered amino acid sequence is unknown; however, the impacted region is critical for protein function (Bruystens JG et al. J Mol Biol, 2016 12;428:4890-4904; Ambry internal data). This alteration was identified in a 30-year-old female with a clinical diagnosis of Carney complex and co-segregated with disease. In addition, this alteration was demonstrated to result in skipping of coding exon 4 (Gennari M et al. Clin Endocrinol (Oxf), 2008 Nov;69:751-5). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at